PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows
For the Year Ended June 30, 2024

Cash flows from operating activities	
Student tuition and fees	$ -
Federal appropriations	-
Grants and contracts	42,060,437
Sales and services of educational departments	728,720
Hospital income	-
Auxiliary enterprise receipts	54,044
Payments for employee compensation	(36,953,343)
Payments for benefits	(13,603,664)
Payments for utilities	(2,392,222)
Payments for supplies and services	(24,035,757)
Payments for scholarships and fellowships	-
Loans to students	-
Collection of loans to students	-
Other receipts (disbursements)	63,885
Net cash provided (used) by operating activities	(34,077,900)
Cash flows from non-capital financing activities	
State appropriations	35,517,174
Gifts and grants for other than capital purposes	1,579,160
Private gifts for endowment purposes	-
TOPS receipts	-
TOPS disbursements	-
FEMA receipts	-
FEMA disbursements	-
Direct lending receipts	-
Direct lending disbursements	-
CARES receipts	-
CARES disbursements	-
Implicit loan to/from other campuses	-
Other receipts (disbursements)	99,999
Net cash provided (used) by noncapital financing sources	37,196,333
Cash flows from capital financing activities	
Proceeds from capital debt	-
Capital appropriations received	-
Capital grants and gifts received	-
Proceeds from sale of capital assets	-
Purchase of capital assets	(1,040,697)
Principal paid on capital debt and leases	-
Interest paid on capital debt and leases	-
Deposit with trustees	-
Receipts from lessor leases	-
Payments for leased assets	(69,628)
Other sources (uses)	-
Net cash provided (used) by capital financing activities	(1,110,325)
Cash flows from investing activities	
Proceeds from sales and maturities of investments	-
Interest received on investments	191,056
Purchase of investments	-
Net cash provided (used) by investing activities	191,056
Net increase (decrease) in cash and cash equivalents	2,199,164
Cash and cash equivalents at the beginning of the year	9,477,437
Cash and cash equivalents at the end of the year	$ 11,676,601

PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows
For the Year Ended June 30, 2024

Reconciliation of Net Operating Revenues (Expenses) to Net Cash Provided (used) by Operating Activities		
Operating loss	$	(37,759,134)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:		
Depreciation expense		4,666,535
Nonemployer contributing entity revenue		669,512
Changes in assets and liabilities		
(Increase) decrease in accounts receivable, net		(1,466,459)
(Increase) decrease in inventories		9,288
(Increase) decrease in prepaid expenses & advances		-
(Increase) decrease in notes receivable		-
(Increase) decrease in deferred outflows related to OPEB		1,132,828
(Increase) decrease in deferred outflows related to pensions		(36,729)
(Increase) decrease in other assets		-
Increase (decrease) in accounts payable & accrued liabilities		(344,047)
Increase (decrease) in unearned revenues		796,624
Increase (decrease) in amounts held in custody for others		-
Increase (decrease) in compensated absences		342,197
Increase (decrease) in OPEB payable		1,392,778
Increase (decrease) in NPL		(2,991,227)
Increase (decrease) in deferred inflows related to leases		-
Increase (decrease) in deferred inflows related to OPEB		(1,227,871)
Increase (decrease) in deferred inflows related to pensions		741,894
Increase (decrease) in other liabilities		(4,089)
Net cash provided (used) by operating activities:		(34,077,900)
Noncash Investing, Noncapital Financing, and Capital & Related Financing Transactions		
Capital appropriations		10,053
Amortized borrowing expense		-
Increase (Decrease) in fair market value of assets		267,085
Non-employer contributing entity revenue		669,512
Capital gifts and grants		-
Transfer/disposal of capital assets		-
Subscription-based IT arrangements in curent year		-
Leased assets in current year		-
Lease receivables in current year		-
Net non-cash transactions		946,650
Reconciliation of Cash & Cash Equivalents to the SNP		
Cash and cash equivalents classified as current assets		6,388,460
Cash and cash equivalents classified as noncurrent assets		5,288,141
	$	11,676,601